EIKANCE (Aspen Pharmacare Australia Pty Ltd)
Product name
EIKANCE
Date registered
Evaluation commenced
Decision date
Approval time
247 (255 working days)
Active ingredients
atropine sulfate monohydrate
Registration type
EOI
Indication
EIKANCE 0.05%, 0.025% and 0.01% are indicated as a treatment to slow the progression of myopia when initiated in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses ≥ 0.5 D or axial length increase of 0.2mm per year.